Quarterly ResultJun 5, 2026, 04:32 PM
SINOVAC Reports 2025 Sales Up to $386M, Posts Net Loss of $59.7M
AI Summary
SINOVAC Biotech Ltd. announced its financial results for the second half and full year ended December 31, 2025. While full-year sales increased to $386.0 million, the company reported a net loss of $59.7 million for the year, a reversal from a net income of $90.9 million in 2024. The company highlighted strong growth in its overseas business, which surged 93.9% to $124.8 million, contributing significantly to overall sales. SINOVAC also filed its annual report on Form 20-F and noted a substantial increase in cash reserves. The company also declared a significant special cash dividend in April 2025.
Key Highlights
- SINOVAC reported sales of $386.0 million for FY2025, an increase from $361.4 million in FY2024.
- Net loss attributable to common shareholders was $59.7 million ($0.83/share) for FY2025, compared to net income of $90.9 million ($1.27/share) in FY2024.
- Sales for H2 2025 were $255.7 million, up from $232.7 million in H2 2024, driven by overseas markets.
- Net loss for H2 2025 was $38.0 million ($0.53/share), a significant increase from a net loss of $2.9 million ($0.04/share) in H2 2024.
- Overseas sales surged 93.9% to $124.8 million in 2025, contributing 32.3% of total sales.
- The company filed its annual report on Form 20-F for the fiscal year ended December 31, 2025.
- Cash and cash equivalents and restricted cash totaled $1.2 billion as of December 31, 2025, up from $602.2 million in 2024.
- A special cash dividend of $55.00 per common share was declared in April 2025.
Price Impact
More from SVA